Loading
A phase 2/3 trial testing HMPL-453 in biliary tract cancer, now recruiting.
HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma is a phase 2/3 interventional study registered as NCT04353375, led by Hutchmed, and recruiting on the registry. Official title: An Open-Label, Single-Arm, Multicenter Phase 2/3b Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-453 Tartrate in Patients With Advanced Intrahepatic Cholangiocarcinoma Habouring FGFR2 Fusion/Rearrangement. Planned enrolment is 235 participants (estimated). The study started in 2020-09-03 and primary completion is expected in 2028-06-30. No results have been posted on ClinicalTrials.gov.